Assess whether pediatric studies are necessary or waivable after a literature

Situation

505(b)(2) literature-to-product bridge table arrived with a literature paper the 505(b)(2) package leans on getting retracted for CMC change-control owner. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on pediatric studies are necessary in a safety team sitting on a new disproportionate signal.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as Pediatric studies are necessary once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Waivable after a literature paper the 505(b)(2) package leans on getting retracted; Pediatric studies are necessary would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in 505(b)(2) literature-to-product bridge table for CMC change-control owner in a safety team sitting on a new disproportionate signal.
• 505(b)(2) literature-to-product bridge table is missing the fact CMC change-control owner needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.